Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia

NCT01109069 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

199

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Diffuse Well-differentiated Lymphocytic Lymphoma
B Cell Lymphoma
Follicular Lymphoma
Mantle Cell Lymphoma
Non-Hodgkin's Lymphoma
Waldenstrom Macroglobulinemia
Burkitt Lymphoma
B-Cell Diffuse Lymphoma

Interventions

DRUG: PCI-32765

Sponsor

Pharmacyclics LLC.

Collaborators

[object Object]